Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

ED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)

(Unaudited)

June 28, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $177,656 $200,132

Available for sale debt and marketable

equity securities 115,306 85,375

Accounts receivable, net 61,284 64,182

Inventories 51,774 84,887

Prepaid expenses and other current assets 15,684 14,294

Deferred income tax assets 54,868 56,921

Income taxes receivable 21,715 17,516

Total current assets 498,287 523,307

Property, plant and equipment, at cost less

accumulated depreciation and amortization 84,771 82,650

Available for sale debt and marketable

equity securities 5,156 6,690

Investment in joint venture - 6,314

Other investments 2,500 2,500

Intangible assets, net 55,350 36,059

Goodwill 63,729 63,729

Deferred financing costs and other assets 2,085 2,544

Non-current deferred income tax assets, net 59,252 57,730

Total assets $771,130 $781,523

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Current portion of long-term debt $200,000 $200,000

Accounts payable
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... Enhances ... Senior Management Team, ROCKVILLE, Md., June 18 EntreMed, ... the treatment of cancer and inflammatory diseases, today,announced the appointment ... and Business Development. Mr. Bliss has been elected,an executive officer ...
... Access to data may provide potential for label expansion ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today ... Bayer,s phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT ... be appropriate for CTI to begin discussions with the,U.S. ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... guidance for full year 2008,revenue to be in the ... year,2008 earnings per adjusted pro-forma fully diluted share (excluding ... IPO) to be in the,range of $0.87 to $0.94. ...
Cached Biology Technology:EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Researchers from the Institute of Food Research and The ... a gut bacterium, to help understand how these organisms ... relationship between gut bacteria and the gastrointestinal tract is ... the role of bacteria in establishing and maintaining gut ...
... , Higher temperatures could significantly impact California and other ... next 30 years, according to a new study led ... June 30 edition of Environmental Research Letters , ... land suitable for cultivating premium wine grapes in high-value ...
... BALTIMORE, June 29, 2011 BD Biosciences, a ... today the availability of BD Recharge™, a chemically ... manufacturing that offers productivity comparable to yeast-based peptones. ... significant advance for biopharmaceutical cell culture," said Robert ...
Cached Biology News:Genome analysis will reveal how bacteria in our guts make themselves at home 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2
For microscopy...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Biology Products: